A Danish judge has ruled that investors are permitted to sue Novo Nordisk for financial losses stemming from disappointing clinical trial results disclosed in 2024.
The decision marks a significant escalation in legal risks for the pharmaceutical giant, which has already faced intense scrutiny over its corporate governance practices.
The ruling allows shareholders who suffered losses during the period surrounding the negative trial data to pursue legal action.
This development adds a new layer of uncertainty for the company, which is already navigating a contentious relationship with major institutional investors.
Earlier this week, Novo Nordisk shares fell sharply in Copenhagen trading after a prominent shareholder publicly condemned the company's oversight mechanisms, describing them as "extremely poor."
The combination of legal exposure and governance criticism presents a dual challenge for management.
While the company remains a dominant force in the diabetes and weight-loss markets, the potential for class-action style litigation could impact its balance sheet and reputation.